Carregant...
Tipus de document
ArticleData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/179012
The role of CDK4/6 inhibitors in early breast cancer
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.
Matèries (anglès)
Citació
Citació
GIL GIL, Miguel, ALBA, Emilio, GAVILÁ, Joaquín, HABA RODRÍGUEZ, Juan de la, CIRUELOS, Eva, TOLOSA, Pablo, CANDINI, Daniele, LLOMBART CUSSAC, Antonio. The role of CDK4/6 inhibitors in early breast cancer. _The Breast_. 2021. Vol. 58, núm. 160-169. [consulta: 29 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/179012]